G1 Therapeutics announced Monday morning that Norman “Ned” Sharpless, former director of the National Cancer Institute, has joined its board of directors.
Sharpless, who led NCI from 2017 until April 2022 and briefly served as acting commissioner of the Food and Drug Administration in 2019, has a long history with G1. He was one of the company’s scientific founders in 2008. Prior to serving in public office, Sharpless divested his holdings in G1.
“I am enthusiastic about the strong development and commercial capabilities of G1 today,,” Sharpless said in a statement. “It has been thrilling as a researcher and physician to watch G1’s technology transform from an early scientific concept from my lab into an FDA-approved medicine with the potential to dramatically improve the outcomes and survivorship of so many patients affected by cancer.”
